| http://www.w3.org/ns/prov#value | - This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the possibility of unfavorable results from additional clinical trials involving an FDC of ranolazine and low-dose dronedarone.
|
